The stock has a 36-month beta value of 3.82. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NMRA is 54.90M, and at present, short sellers hold a 17.63% of that float. On October 16, 2024, the average trading volume of NMRA was 738.03K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NMRA) stock’s latest price update
The stock of Neumora Therapeutics Inc. (NASDAQ: NMRA) has increased by 3.08 when compared to last closing price of 15.60.Despite this, the company has seen a gain of 9.09% in its stock price over the last five trading days. globenewswire.com reported 2024-08-14 that Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET
NMRA’s Market Performance
Neumora Therapeutics Inc. (NMRA) has seen a 9.09% rise in stock performance for the week, with a 34.67% gain in the past month and a 35.13% surge in the past quarter. The volatility ratio for the week is 8.89%, and the volatility levels for the past 30 days are at 7.00% for NMRA. The simple moving average for the last 20 days is 16.10% for NMRA’s stock, with a simple moving average of 25.45% for the last 200 days.
Analysts’ Opinion of NMRA
Many brokerage firms have already submitted their reports for NMRA stocks, with H.C. Wainwright repeating the rating for NMRA by listing it as a “Buy.” The predicted price for NMRA in the upcoming period, according to H.C. Wainwright is $30 based on the research report published on October 01, 2024 of the current year 2024.
Needham, on the other hand, stated in their research note that they expect to see NMRA reach a price target of $23. The rating they have provided for NMRA stocks is “Buy” according to the report published on July 22nd, 2024.
Mizuho gave a rating of “Outperform” to NMRA, setting the target price at $20 in the report published on July 08th of the current year.
NMRA Trading at 29.45% from the 50-Day Moving Average
After a stumble in the market that brought NMRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.43% of loss for the given period.
Volatility was left at 7.00%, however, over the last 30 days, the volatility rate increased by 8.89%, as shares surge +37.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +34.45% upper at present.
During the last 5 trading sessions, NMRA rose by +9.09%, which changed the moving average for the period of 200-days by -6.18% in comparison to the 20-day moving average, which settled at $13.85. In addition, Neumora Therapeutics Inc. saw -5.69% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NMRA starting from Lenz Robert A., who sale 8,260 shares at the price of $15.09 back on Oct 10 ’24. After this action, Lenz Robert A. now owns 314,706 shares of Neumora Therapeutics Inc., valued at $124,603 using the latest closing price.
Lenz Robert A., the Head of R&D of Neumora Therapeutics Inc., sale 5,563 shares at $15.01 during a trade that took place back on Oct 09 ’24, which means that Lenz Robert A. is holding 322,966 shares at $83,507 based on the most recent closing price.
Stock Fundamentals for NMRA
The total capital return value is set at -0.77. Equity return is now at value -77.08, with -71.73 for asset returns.
Based on Neumora Therapeutics Inc. (NMRA), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -54.98.
Currently, EBITDA for the company is -187.53 million with net debt to EBITDA at 0.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.22.
Conclusion
To sum up, Neumora Therapeutics Inc. (NMRA) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
